Reply to: Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual ...

Investigators assessed whether a reported survival disadvantage in men with secondary rectal cancer following prostate cancer radiation therapy vs primary rectal cancer is due to patient ...

PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented by Andrea Cercek, MD, at the AACR Annual ...

neoadjuvant therapy in breast cancer, total neoadjuvant therapy in rectal cancer, and the use of biomarkers to inform ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...